Related Experiment Video
Updated: Mar 31, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
821
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Jose Luis Górriz1,2,3, Javier Nieto4,5, Juan F Navarro-González6,7,8
1Hospital Universitario Dr Peset, Universidad de Valencia, Valencia 46017, Spain. jlgorriz@senefro.org.
Journal of Clinical Medicine
|October 30, 2015
Summary
Current diabetic nephropathy therapies offer incomplete renal protection. While some antihyperglycemic drugs show potential kidney benefits beyond glucose control, more clinical trials are needed to confirm their nephroprotective effects.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy (DN) therapies like glycemic control and blood pressure management provide incomplete renal protection.
- A gap exists in understanding the nephroprotective effects of antihyperglycemic drugs beyond their glucose-lowering capabilities.
Purpose of the Study:
- To analyze existing data on older and newer antihyperglycemic drugs and their mechanisms in preventing and progressing diabetic nephropathy.
- To evaluate the potential of these drugs to improve renal outcomes independently of glycemic control.
Main Methods:
- Review of existing experimental and clinical trial data on antihyperglycemic drugs.
- Analysis of post hoc studies from clinical trials investigating renal effects.
Main Results:
- Experimental data suggest some antihyperglycemic drugs may benefit kidney parameters.
- Clinical evidence for significant nephroprotection beyond glucose lowering is limited, with some promising signals for DPP-4 inhibitors, GLP-1 RAs, and SGLT2 inhibitors.
Conclusions:
- Antihyperglycemic drugs may offer renal protection beyond glycemic control, but robust clinical evidence is lacking.
- Dedicated renal outcome trials are essential to definitively assess the nephroprotective role of antihyperglycemic agents in diabetic nephropathy.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
621
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
621
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
487
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
487
01:06Oral Hypoglycemic Agents: Glinides
938
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
938
01:20Acute Kidney Injury V: Interprofessional Care
463
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
463
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:24Nephrotic Syndrome I : Introduction
970
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
970